Market Place
Sourcing Support
Ryvu Presents RVU120 Data At EHA 2024 Congress
14 Jun 2024 //
PR NEWSWIRE
MorphoSys`s Pelabresib Myelofibrosis Data in ASCO Oral Session
24 Apr 2024 //
ACCESSWIRE
Novartis to acquire cancer-centric MorphoSys for $2.9 bln
06 Feb 2024 //
PRESS RELEASE
MorphoSys’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3
10 Dec 2023 //
BUSINESSWIRE
MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Improvement
20 Nov 2023 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.